Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Summary

Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma. Its presence in maternal plasma has allowed development of noninvasive prenatal diagnosis for single-gene disorders (SGD-NIPD). This can be performed from 9 weeks of amenorrhea and offers an early, safe and accurate definitive diagnosis without the miscarriage risk associated with invasive procedures. One of the major difficulties is distinguishing fetal genotype in the high background of maternal cfDNA, which leads to several technical and analytical challenges. Besides, unlike noninvasive prenatal testing for aneuploidy, NIPD for monogenic diseases represent a smaller market opportunity, and many cases must be provided on a bespoke, patient- or disease-specific basis. As a result, implementation of SGD-NIPD remained sparse, with most testing being delivered in a research setting. The present project aims to take advantage of the unique French collaborative network to make SGD-NIPD possible for theoretically any monogenic disorder and any family.

Eligibility

Inclusion Criteria:

* pregnant woman with 9 weeks of amenorrhea or more
* singleton pregnancy
* undergoing invasive PND in a context of family history of SGD involving the following genes : HBB, CFTR, FMR1, SMN1, DMPK, DMD, NF1, HTT, F8, F9, GCK, L1CAM, PKHD1, or undergoing prenatal counselling in a context of maternal history of diabetes MODY-GCK
* germinal pathogenic paternal and/or maternal mutations previously identified
* age 18 years old or over
* signing an informed consent

Exclusion Criteria:

* at risk of SGD involving a de novo pathogenic mutation in a previous child
* woman under legal protection

Conditions18

Interventions1

Related trials

• Angiogenic Biomarkers in Juvenile Idiopathic Arthritis — Assistance Publique - Hôpitaux de Paris
• Basal Plasma Lithium Levels and Suicidal Events — University Hospital, Montpellier
• Characterization of Natural Killer Cells in Severe Asthma Patients in Comparison With Control Subjects — Institut National de la Santé Et de la Recherche Médicale, France
• Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia — Centre Hospitalier Universitaire, Amiens
• Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas — Assistance Publique Hopitaux De Marseille
• Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial — Centre Hospitalier Universitaire, Amiens
• Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways — Assistance Publique Hopitaux De Marseille
• Detection of ISUP≥2 Prostate Cancers Using Multiparametric MRI: Prospective Multicenter Comparison of the PI-RADS Score and an Artificial Intelligence System — Hospices Civils de Lyon

Browse More Trials